Reversible stiffening of light weight mesh

• US 9,526,603 B2
• Filed: 10/01/2012
• Issued: 12/27/2016
• Est. Priority Date: 09/30/2011
• Status: Active Grant

• Current Assignee: Covidien LP (Medtronic Plc), Sofradim Production
• Original Assignee: Covidien LP (Medtronic Plc), Sofradim Production
• Inventors: Hadba, Ahmad Robert, Lefranc, Olivier, Buffinton, Jennifer
• Primary Examiner(s): Barham, Bethany
• Assistant Examiner(s): FRAZIER, BARBARA S
• Application Number:
  US14/345,810
• Publication Number:
  US 20140236199A1
• Time in Patent Office: 1,548 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61F 2/0063 Implantable repair or support meshes, e.g. hernia meshes
• CPC Class Codes: A61L 2420/06 Coatings containing a mixture of two or more compounds
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

An implant and a process for preparing such an implant are disclosed. The implant includes a mesh including a biodegradable polymeric coating having glass transition temperature of about 26° C. to about 36° C. The polymeric coating includes a first polymeric component including a lactone and a second polymeric component including a polyether. The first polymeric component is present in an amount from about 90% to about 99% of the polymeric coating and the second polymeric component is present in an amount from about 1% to about 10% of the polymeric coating.

Claims

1. An implant comprising:

a mesh including a biodegradable polymeric coating, the biodegradable polymeric coating comprising;

a first polymeric component including a lactone present in an amount from about 90% to about 99% by weight of the polymeric coating; and

a second polymeric component including a fatty acid diester of polyethylene glycol present in an amount from about 1% to about 10% by weight of the polymeric coating,

wherein the biodegradable polymeric coating has a glass transition temperature of from about 26°

C. to about 36°

C.

2. The implant of claim 1, wherein the biodegradable polymeric coating has a glass transition temperature of about 30°

C. to about 35°

C.

3. The implant of claim 1, wherein the first polymeric component is selected from the group consisting of glycolide, lactide, p-dioxanone, ε

-caprolactone, trimethylene caprolactone, orthoester, phosphoester, copolymers, and blends thereof.

4. The implant of claim 1, wherein the first polymeric component is a copolymer of glycolide and lactide.

5. The implant of claim 4, wherein glycolide is present in an amount from about 10% to about 50% by weight of the copolymer and lactide is present in an amount from about 50% to about 90% by weight of the copolymer.

6. The implant of claim 4, wherein glycolide is present in an amount from about 15% to about 40% by weight of the copolymer and lactide is present in an amount from about 60% to about 85% by weight of the copolymer.

7. The implant of claim 1, wherein the polyethylene glycol has a molecular weight from about 200 g/mol to about 1000 g/mol.

8. The implant of claim 1, wherein the polyethylene glycol has a molecular weight from about 600 g/mol to about 900 g/mol.

9. The implant of claim 1, wherein the polymeric coating comprises from about 95% to about 99% by weight of the first polymeric component and from about 1% to about 5% by weight of the second polymeric component.

10. The implant of claim 1, wherein the polymeric coating comprises from about 97% to about 99% by weight of the first polymeric component and from about 1% to about 3% by weight of the second polymeric component.

11. The implant of claim 1, wherein the mesh further includes a bioactive agent.

12. A process for coating a surgical mesh comprising:

preparing a solution by dissolving a first polymeric component comprising a lactone and a second polymeric component comprising a fatty acid diester of polyethylene glycol in a solvent;

coating the surgical mesh with the solution to form a polymeric coating on the surgical mesh; and

drying the polymeric coating on the surgical mesh,

wherein the lactone is present in the polymeric coating in an amount from about 90% to about 99% by weight of the polymeric coating, the fatty acid diester of polyethylene glycol is present in an amount from about 1% to about 10% by weight of the polymeric coating, and the polymeric coating has a glass transition temperature of about 26°

C. to about 36°

C.

13. The process of claim 12, wherein the first polymeric component is selected from the group consisting of glycolide, lactide, p-dioxanone, ε

-caprolactone, trimethylene caprolactone, orthoester, phosphoester, copolymers, and blends thereof.

14. The process of claim 12, wherein the solvent is selected from the group consisting of hexafluoroisopropanol, acetone, ethylene acetate, isopropanol, methylene chloride, chloroform, tetrahydrofuran, dimethyl formamide, n-methyl pyrrolidone, and combinations thereof.

15. The process of claim 12, wherein the surgical mesh is coated by a process selected from the group consisting of spray coating, ultrasonic spray coating, electrospray coating, dip coating, solvent evaporation, and combinations thereof.

16. The process of claim 12, wherein the polymeric coating comprises from about 95% to about 99% by weight of the first polymeric component and from about 1% to about 5% by weight of the second polymeric component.

17. The process of claim 12, wherein the polymeric coating comprises from about 97% to about 99% by weight of the first polymeric component and from about 1% to about 3% by weight of the second polymeric component.

18. The process of claim 12, wherein the polymeric coating further includes a bioactive agent.